Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group
Jason N. BermanChildren's Oncology Group, Arcadia, CA, USARobert B. GerbingChildren's Oncology Group, Arcadia, CA, USATodd A. AlonzoChildren's Oncology GroupPhoenix A. HoClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAKristen L. MillerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USACraig A. HurwitzReata Pharmaceuticals, Dallas, TX, USANyla A. HeeremaDepartment of Pathology, The Ohio State University, Columbus, OH, USABetsy HirschDepartment of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, Minneapolis, MN, USASusana C. RaimondiDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USABeverly J. LangeDepartment of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USAJanet FranklinAmgen Pharmaceuticals, Thousand Oaks, CA, USAAlan S. GamisDivision of Hematology/Oncology/Bone Marrow Transplantation, Children′s Mercy Hospital & Clinics, Kansas City, MO, USASoheil MeshinchiChildren's Oncology Group, Arcadia, CA, USA
2011en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0